⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLTE News
Belite Bio, Inc American Depositary Shares
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
globenewswire.com
BLTE
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
globenewswire.com
BLTE
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
globenewswire.com
BLTE
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
globenewswire.com
BLTE
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
KODK
RKDA
OTLK
UTHR
CLSD
AZN
BTE
CCNE
IONS
APLS
GYRO
NVS
GNTX
BLTE
JNJ
LCTX
ABBV
REGN
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
globenewswire.com
BLTE
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
BLTE
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com
BLTE
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
globenewswire.com
BLTE
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
globenewswire.com
BLTE